7-phenethyl-7-azaspiro[3.5]nonan-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-phenethyl-7-azaspiro[3.5]nonan-1-one
• 英文别名: 7-(2-Phenylethyl)-7-azaspiro[3.5]nonan-3-one；7-(2-phenylethyl)-7-azaspiro[3.5]nonan-3-one
• 化学式: C₁₆H₂₁NO
• 分子量: 243.349
• InChiKey: IWDNPQLXJJUONF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  7-azaspiro[3.5]nonan-1-one 、 乙基溴苯 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 18.0h， 生成 7-phenethyl-7-azaspiro[3.5]nonan-1-one
  参考文献：
  名称：

  [EN] ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES
  [FR] COMPOSÉS INHIBITEURS DE CANAUX IONIQUES, FORMULATIONS PHARMACEUTIQUES, ET UTILISATIONS

  摘要：

  本发明主要针对新的化学实体，其主要抑制人类T型钙通道，并差异调节其他关键离子通道，以控制细胞兴奋性，以及参与持续性或慢性疼痛的发展和维持，和/或神经系统疾病的异常神经元活动。这些新颖化合物对治疗和预防这些离子通道参与的神经和精神疾病和疾病具有用处。该发明还涉及包含这些化合物的药物配方以及这些化合物的用途。

  公开号：

  WO2017083867A1

文献信息

• Ion channel inhibitory compounds, pharmaceutical formulations, and uses
  申请人：AFASCI, Inc.

  公开号：US10562857B2

  公开（公告）日：2020-02-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and/or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明针对的新化学实体主要抑制人类 T 型钙通道，并对其他关键离子通道进行不同程度的调节，以控制细胞兴奋性和异常神经元活动，特别是与持续或慢性疼痛和/或神经紊乱的发展和维持有关的异常神经元活动。这些新型化合物可用于治疗和预防涉及这些离子通道的神经和精神疾病。本发明还涉及包含这些化合物的药物制剂以及这些化合物的用途。
• ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES
  申请人：Afasci, Inc.

  公开号：EP3340988A1

  公开（公告）日：2018-07-04
• Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses
  申请人：AFASCI, Inc.

  公开号：US20180312471A1

  公开（公告）日：2018-11-01

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and/or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.
• [EN] ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES<br/>[FR] COMPOSÉS INHIBITEURS DE CANAUX IONIQUES, FORMULATIONS PHARMACEUTIQUES, ET UTILISATIONS
  申请人：AFASCI INC

  公开号：WO2017083867A1

  公开（公告）日：2017-05-18

  The present invention is directed towards new chemical entities which primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity particularly involved in the development and maintenance of persistent or chronic pain, and / or neurological disorders. These novel compounds are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which these ion channels are involved. The invention is also directed towards pharmaceutical formulations comprising these compounds and the uses of these compounds.

  本发明主要针对新的化学实体，其主要抑制人类T型钙通道，并差异调节其他关键离子通道，以控制细胞兴奋性，以及参与持续性或慢性疼痛的发展和维持，和/或神经系统疾病的异常神经元活动。这些新颖化合物对治疗和预防这些离子通道参与的神经和精神疾病和疾病具有用处。该发明还涉及包含这些化合物的药物配方以及这些化合物的用途。